BASKING RIDGE, N.J., March 15 Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, announced that Chris Rusconi, PhD, Senior Vice President, Chief Scientific Officer and Steven Zelenkofske, DO, FACC, Senior Vice President , Chief Medical Officer presented an abstract at the American College of Cardiology on Monday, March 15, 2010 in Atlanta, Georgia. The poster, entitled "Subcutaneous FIXa Inhibitor Provides Prolonged Anticoagulation: The First Successful Subcutaneous Application of an Aptamer," is the first presentation of data from Regado's pre-clinical study of its REG2 anticoagulation system, currently in Phase 1 human clinical testing. The REG2 system is Regado's second product candidate in development, which consists of a subcutaneously administered formulation of the specific Factor IXa inhibitor, RB006, paired with an IV bolus formulation of its complementary active control agent, RB007. The abstract is coauthored by Doug Kornbrust, Chris Rusconi and Steven Zelenkofske from Regado Biosciences. "We were pleased to find that the subcutaneous administration of RB006 was well tolerated in primates and achieved prolonged anticoagulation that was reversible by RB007. This represents the first successful subcutaneous application of an aptamer," stated Dr. Rusconi. In addition, Dr. Zelenkofske added: "The prolonged anticoagulant effect and reversibility may provide a new approach to sub-acute anticoagulation for future clinical applications."
ABOUT REGADO BIOSCIENCES
Regado Biosciences is pioneering a new therapeutic technology with the creation and development of two-component drug systems. Each system comprises a nuclease-stabilized RNA aptamer that can be controlled directly by its specific and complementary oligonucleotide active control agent. This technology is being applied to injectable antithrombotics, including anticoagulants and antiplatelet agents, a multi-billion dollar market in need of therapeutics with improved safety profiles and a greater degree of therapeutic control. Regado's technology is designed to give physicians the ability to actively and directly control each system's therapeutic effect providing a safe and unique approach to personalized medicine.
ABOUT REG1 and REG2
Regado's lead program, the anticoagulant system REG1, consists of two parenteral agents both administered by IV bolus, the first being a potent highly selective Factor IXa inhibitor (RB006) and the second being its complementary active control agent (RB007). RB007 can be used to selectively completely or partially reverse the anticoagulant effect of RB006. REG1, presently in phase 2b clinical trial, is intended for application in arterial thrombosis applications, initially in Acute Coronary Syndrome patients undergoing Percutaneous Coronary Intervention. REG2, Regado's second product candidate, consists of a subcutaneously administered depot formulation of RB006 paired with the IV bolus formulation of RB007. REG2 recently completed single escalating dose phase 1 clinical testing and is planned to be studied in a multiple escalating dose clinical trial later in 2010. It is intended for use in venous thrombosis indications such as venous thromboembolism (VTE) prophylaxis in patients undergoing abdominal surgery. Information pertaining to Regado's clinical programs may be obtained at www.clinicaltrials.gov.
RB006 is a member of a class of compounds called aptamers. Aptamers are single stranded oligonucleotides that adopt a specific conformation enabling direct, specific inhibition of the targeted protein. A key unique feature of aptamers derives from the fact that they are formed from nucleic acids. As such, their pharmacologic activity can be controlled by a matched, complementary oligonucleotide active control agent (the Watson-Crick base pair complement of a fraction of the agent to be controlled), which can bind to the aptamer, removing it from its target and reversing it biologic effects.
More information can be found at www.regadobio.com
SOURCE Regado Biosciences, Inc.